Successful treatment of cystoid macular edema with valdecoxib.
OBJECTIVE
To evaluate the safety and efficacy of the COX-2 inhibitor valdecoxib in treating macular edema after cataract surgery.


METHODS
University Eye Clinic, Freiburg, Germany and Reis Medical Institution, Liechtenstein.


METHODS
The COX-2 inhibitor valdecoxib (Bextra) was administered systemically to patients with significant visual loss resulting from macular edema in a prospective clinical trial.


RESULTS
Ten patients were enrolled. Valdecoxib was tolerated well and led to a significant visual improvement within 10 days of therapy in all patients.


CONCLUSIONS
The fast and persistent control of macular edema with valdecoxib warrants further investigation.
Reis
Alexander
A
Eye Clinic, University of Freiburg, Freiburg, Germany. reis@augenwerk.li
Birnbaum
Florian
F
Hansen
Lutz L
LL
Reinhard
Thomas
T
D000368:Aged; D000369:Aged, 80 and over; D052246:Cyclooxygenase 2 Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007555:Isoxazoles / Q000009:adverse effects / Q000627:therapeutic use*; D019654:Lens Implantation, Intraocular; D008269:Macular Edema / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D018918:Phacoemulsification; D011183:Postoperative Complications; D011446:Prospective Studies; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use*; D014792:Visual Acuity; D000096926:Benzenesulfonamides
D052246:Cyclooxygenase 2 Inhibitors; D007555:Isoxazoles; D013449:Sulfonamides; C406224:valdecoxib; D000096926:Benzenesulfonamides